Granules India receives FDA approval for generic antidepressant medication

- Advertisement - (adsbygoogle = window.adsbygoogle || []).push({});

Mumbai, India (CU)_ Indian pharma Granules India announced on Thursday that the US Food and Drug Administration has granted permission to sell Bupropion Hydrochloride extended-release tablets, an antidepressant medication, in the American market. According to the statement from the Hyderabad-based pharma firm, the US Food and Drug Administration (USFDA) has authorized Granules Pharmaceuticals, Inc (GPI), a wholly-owned subsidiary of the company, to market the medication in 150 mg and 300 mg dosages.

The firm’s product is a generic version of Wellbutrin XL extended-release tablets manufactured by Bausch Health US, LLC. The antidepressant medication bupropion hydrochloride is widely employed in addressing major depressive disorder and seasonal affective disorder.

Priyanka Chigurupati, Executive Director of GPI, expressed delight over the approval and the company’s expansion into the US market. He stated, “We are pleased to receive approval of Bupropion Hydrochloride (XL) tablet product within first review cycle of 10 months from filing date. This product will be a valuable addition to our growing modified release product portfolio in the US market”.

dsij.in

This product will complement the firm’s growing portfolio of modified release products in the US market. According to MAT Dec 2021, IQVIA/IMS Health, the US market for Bupropion Hydrochloride extended-release tablets at present is worth approximately USD 661 million per year. Granules reported that it currently owns 50 abbreviated new drug application (ANDA) approvals received from the US Food and Drug Administration.

Granules India Limited is an Indian pharmaceutical manufacturing giant headquartered in Hyderabad, India. Granules manufactures numerous off-patent drugs, such as Paracetamol, Ibuprofen, Metformin and Guaifenesin, on a large scale basis for customers in the regulated and rest of the global markets. Granules India Limited entered CRAMS segment, which specializes on contract research and manufacturing.

A Personal Note from the Publisher" Small photo of you, with your signature beneath

A Personal Note from the Publisher

My dear friend, thank you for your time with us today. This site was built for you, the members of the Commonwealth Family, and nothing matters more to me than hearing your voice and feedback.

What did you make of this article? Did it inform you, challenge you, or leave you wanting more?

Please tell me. I read your replies personally and they help shape everything we publish.

With warmest wishes,
Hon. Nirj Deva
Founder and Publisher.

Free, always. We'll never sell your details.

spot_img

Hot this week

India’s Gold Revolution: You Can Now Own Gold Without Ever Holding It—What Is Changing?

MUMBAI, INDIA — 20 NOVEMBER 2026 People in India have...

Malta’s New Tourist Tax Set to Exceed Rates in Competing Mediterranean Destinations

Travellers planning a holiday in Malta will soon face...

TSMC Tightens Chip Manufacturing Rules for Chinese Companies After New US Export Controls

The world’s largest contract chipmaker, Taiwan Semiconductor Manufacturing Co...

Jamaica and the United States Sign Customs Agreement to Bolster Border Security

Jamaica and the United States have signed a new...

The Flight Was Over, But the Danger Wasn’t: Why Two Virgin Australia Pilots Refused to Fly Again

ADELAIDE, AUSTRALIA — 20 NOVEMBER 2026 It is possible for...
- Advertisement - (adsbygoogle = window.adsbygoogle || []).push({});

Related Articles

- Advertisement -sitaramatravels.comsitaramatravels.com

Popular Categories